Chuck Bramlage

Chuck Bramlage is a veteran commercial executive who has contributed to dozens of product launches across a range of therapeutic areas during his career. He is currently Chief Executive Officer of Yamo Pharmaceuticals, following a tenure as Chief Executive Officer of Pearl Therapeutics, which was previously acquired by AstraZeneca. His earlier roles include Chief Operations Officer of Pharmaceutical Products at Covidien plc., President of European operations at Valeant Pharmaceuticals International, President/CEO of BattellePharma, Inc., Vice President of Respiratory Global Commercial Development and Vice President of U.S. respiratory and cardiovascular marketing for GlaxoSmithKline.  Mr. Bramlage holds a bachelor’s degree in marketing from The Ohio State University and an MBA from the University of Dayton.